American Journal of Biomedical and Life Sciences

Special Issue

Tanopati, a Cardioprotective Drug Derived from Traditional Medicine

  • Submission Deadline: Jun. 10, 2020
  • Status: Submission Closed
  • Lead Guest Editor: Komenan Nazaire Amani
About This Special Issue
Doxorubicin (dox) is one of the most effective antitumor antibiotics belonging to the class of anthracyclines. However, its use is limited by a high incidence of irreversible myocardial damage and dilatation.
Several approaches may be taken to decrease the risk of dox-induced cardiotoxicity while maintaining its efficacy. These include altered schedules of drug administration, modifications of the anthracycline molecule, adjunctive treatment with beta-adrenergic blockers, angiotensin-converting enzyme inhibitors (ACEi), dexrazoxane, and probucol. None of these have been entirely successful. A new drug to prevent or treat Dox-induced cardiotoxicity is therefore needed.
The therapeutic actions of most medicinal plants are related to their antioxidant properties which, in turn, could be ascribed to their antioxidant phytochemicals. The cardioprotective effect of various medicinal plants and plant products have been documented. Sustainable agents from natural sources could serve as viable alternatives to currently available synthetic drugs in the management of cardiovascular-related disorders. This is especially important owing to the toxic side effects of most synthetic drugs and their high costs which make them not readily accessible to many patients in developing countries like Cote d’Ivoire.
Aims and Scope:
  1. Tanopati
  2. Cardioprotectve
  3. Doxorubicine
  4. Antioxidant
  5. Free Radicals
  6. Traditional Medicine
Lead Guest Editor
  • Komenan Nazaire Amani

    Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouet-Boigny University, Abidjan, Ivory Coast

Guest Editors
  • Konan Kouassi

    Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University, Abidjan, Ivory Coast

  • Rita Bouagnon

    Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University, Abidjan, Ivory Coast

  • Alain Dit Philippe Bidie

    Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University, Abidjan, Ivory Coast

  • Allico Joseph Djaman

    Department of Medical and Fundamental Biochemistry, Pasteur Institute, Abidjan, Ivory Coast

  • Jean David N’Guessan

    Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University, Abidjan, Ivory Coast

  • Houphouet Felix Yapi

    Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University, Abidjan, Ivory Coast